ACOG vs. ARVN, TSHA, CGEM, ETON, ALT, SANA, MGTX, MAZE, SIGA, and ZVRA
Should you be buying Alpha Cognition stock or one of its competitors? The main competitors of Alpha Cognition include Arvinas (ARVN), Taysha Gene Therapies (TSHA), Cullinan Therapeutics (CGEM), Eton Pharmaceuticals (ETON), Altimmune (ALT), Sana Biotechnology (SANA), MeiraGTx (MGTX), Maze Therapeutics (MAZE), SIGA Technologies (SIGA), and Zevra Therapeutics (ZVRA). These companies are all part of the "pharmaceutical products" industry.
Alpha Cognition vs.
Arvinas (NASDAQ:ARVN) and Alpha Cognition (NASDAQ:ACOG) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, community ranking, valuation, risk and institutional ownership.
Alpha Cognition has lower revenue, but higher earnings than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than Alpha Cognition, indicating that it is currently the more affordable of the two stocks.
In the previous week, Arvinas had 1 more articles in the media than Alpha Cognition. MarketBeat recorded 7 mentions for Arvinas and 6 mentions for Alpha Cognition. Alpha Cognition's average media sentiment score of 0.33 beat Arvinas' score of 0.20 indicating that Alpha Cognition is being referred to more favorably in the news media.
95.2% of Arvinas shares are held by institutional investors. 4.7% of Arvinas shares are held by company insiders. Comparatively, 14.0% of Alpha Cognition shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Arvinas has a beta of 2.21, suggesting that its share price is 121% more volatile than the S&P 500. Comparatively, Alpha Cognition has a beta of 2.48, suggesting that its share price is 148% more volatile than the S&P 500.
Arvinas received 201 more outperform votes than Alpha Cognition when rated by MarketBeat users. However, 75.00% of users gave Alpha Cognition an outperform vote while only 65.81% of users gave Arvinas an outperform vote.
Arvinas currently has a consensus price target of $20.92, suggesting a potential upside of 218.37%. Alpha Cognition has a consensus price target of $20.00, suggesting a potential upside of 92.31%. Given Arvinas' higher probable upside, analysts plainly believe Arvinas is more favorable than Alpha Cognition.
Alpha Cognition has a net margin of 0.00% compared to Arvinas' net margin of -75.51%. Alpha Cognition's return on equity of 0.00% beat Arvinas' return on equity.
Summary
Arvinas and Alpha Cognition tied by winning 9 of the 18 factors compared between the two stocks.
Get Alpha Cognition News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACOG and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alpha Cognition Competitors List
Related Companies and Tools
This page (NASDAQ:ACOG) was last updated on 5/21/2025 by MarketBeat.com Staff
